Literature DB >> 7774666

Naloxone reduces the neurochemical and behavioral effects of amphetamine but not those of cocaine.

C A Schad1, J B Justice, S G Holtzman.   

Abstract

The specific opioid receptor antagonist naloxone modifies the effects of amphetamine in a wide variety of behavioral paradigms. Naloxone also attenuates the amphetamine-induced increase in extracellular dopamine in the brain of rats. Therefore, these experiments were designed to replicate the neurochemical and behavioral interactions between naloxone and amphetamine, and to extend these observations to interactions between naloxone and cocaine. Microdialysis was performed on adult male rats of Sprague-Dawley descent. Rats were pretreated with a subcutaneous injection of 5.0 mg/kg naloxone or vehicle, which was followed 30 min later by cumulative doses of subcutaneous d-amphetamine (0.0, 0.1, 0.4, 1.6, 6.4 mg/kg) or intraperitoneal cocaine (0, 3, 10, 30, 56 mg/kg) at 30 min intervals. The microdialysis probes were perfused at a flow rate of 0.6 microliter/min with artificial cerebrospinal fluid. Dialysate samples were collected every 10 min from either the nucleus accumbens or striatum and analyzed for dopamine content by high-performance liquid chromatography (HPLC). Locomotor activity (photobeam breaks) was monitored simultaneously with the collection of dialysate samples. Amphetamine and cocaine dose-dependently increased extracellular dopamine in both the nucleus accumbens and striatum. Naloxone pretreatment significantly reduced the amphetamine-induced increase in extracellular dopamine in both brain regions and also attenuated the increase in locomotor activity elicited by amphetamine. Naloxone pretreatment had no effect, however, on the cocaine-induced increase in extracellular dopamine or locomotor activity. These findings suggest that endogenous opioid systems play a role in mediating the neurochemical and behavioral effects of amphetamine, but not those of cocaine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7774666     DOI: 10.1016/0014-2999(94)00726-n

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

1.  Interactions between opioids and cocaine on locomotor activity in rats: influence of an opioid's relative efficacy at the mu receptor.

Authors:  Mark A Smith; Keith A Gordon; Christopher K Craig; Paul A Bryant; M Eric Ferguson; Adam M French; Jason D Gray; Jacob M McClean; Jonathan C Tetirick
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

2.  Microdialysis and mass spectrometric monitoring of dopamine and enkephalins in the globus pallidus reveal reciprocal interactions that regulate movement.

Authors:  Omar S Mabrouk; Qiang Li; Peng Song; Robert T Kennedy
Journal:  J Neurochem       Date:  2011-05-25       Impact factor: 5.372

3.  Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone.

Authors:  Chi-Tso Chiu; Tangeng Ma; Ing K Ho
Journal:  Brain Res Bull       Date:  2005-09-30       Impact factor: 4.077

4.  The effects of lobeline and naltrexone on methamphetamine-induced place preference and striatal dopamine and serotonin levels in adolescent rats with a history of maternal separation.

Authors:  J J Dimatelis; V A Russell; D J Stein; W M Daniels
Journal:  Metab Brain Dis       Date:  2012-03-04       Impact factor: 3.584

5.  Pain-related depression of the mesolimbic dopamine system in rats: expression, blockade by analgesics, and role of endogenous κ-opioids.

Authors:  Michael D Leitl; Sara Onvani; M Scott Bowers; Kejun Cheng; Kenner C Rice; William A Carlezon; Matthew L Banks; S Stevens Negus
Journal:  Neuropsychopharmacology       Date:  2013-09-06       Impact factor: 7.853

6.  Naltrexone decreases D-amphetamine and ethanol self-administration in rhesus monkeys.

Authors:  Corina Jimenez-Gomez; Gail Winger; Reginald L Dean; Daniel R Deaver; James H Woods
Journal:  Behav Pharmacol       Date:  2011-02       Impact factor: 2.293

7.  Extended-Release Injectable Naltrexone (XR-NTX) With Intensive Psychosocial Therapy for Amphetamine-Dependent Persons Seeking Treatment: A Placebo-Controlled Trial.

Authors:  Valgerdur Runarsdottir; Ingunn Hansdottir; Thorarinn Tyrfingsson; Magnus Einarsson; Karen Dugosh; Charlotte Royer-Malvestuto; Helen Pettinati; Jag Khalsa; George E Woody
Journal:  J Addict Med       Date:  2017 May/Jun       Impact factor: 3.702

8.  Monoaminergic psychomotor stimulants: discriminative stimulus effects and dopamine efflux.

Authors:  Rajeev I Desai; Carol A Paronis; Jared Martin; Ramya Desai; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2010-02-26       Impact factor: 4.030

9.  Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users.

Authors:  Katherine R Marks; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

Review 10.  Roles of micro-opioid receptors in GABAergic synaptic transmission in the striosome and matrix compartments of the striatum.

Authors:  Masami Miura; Masao Masuda; Toshihiko Aosaki
Journal:  Mol Neurobiol       Date:  2008-05-13       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.